LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

LLY

1,010.33

+1.95%↑

JNJ

228.54

+0.2%↑

ABBV

214.5

+2.69%↑

UNH

391.82

+1.33%↑

AZN

185.21

+0.47%↑

Home・Elenco Azioni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Chiusa

SettoreSettore sanitario

19.64 -5.35

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.92

Massimo

20.77

Metriche Chiave
By Trading Economics
Entrata	-29M -11M
Vendite	-24M 105M
EPS	-0.09
Margine di Profitto	-10.717
Dipendenti	354
EBITDA	-31M -8.5M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+62.43% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-281M 2.7B
Apertura precedente	24.99
Chiusura precedente	19.64

Notizie sul Sentiment di mercato

By Acuity

50%

157 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

12.42 / 14.93 Supporto e resistenza

Arcutis Biotherapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 mag 2026, 23:10 UTC

Azioni calde

Stocks to Watch: Agilysys, XP

18 mag 2026, 18:44 UTC

I principali Market Mover

Claritev Shares Recover After Comments About DOJ

18 mag 2026, 23:55 UTC

Utili

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mag 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

18 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mag 2026, 23:37 UTC

Discorsi di Mercato

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mag 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mag 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

18 mag 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

18 mag 2026, 20:25 UTC

Utili

Correct: XP 1Q Total Client Assets BRL1.53T

18 mag 2026, 20:23 UTC

Utili

XP 1Q Total Client Assets BRL1.53B

18 mag 2026, 20:19 UTC

Utili

XP 1Q Adj EPS BRL2.49 >XP

18 mag 2026, 20:19 UTC

Utili

XP 1Q Rev BRL4.73B >XP

18 mag 2026, 19:10 UTC

Discorsi di Mercato

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mag 2026, 19:00 UTC

Utili

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mag 2026, 18:52 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mag 2026, 18:17 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mag 2026, 17:22 UTC

Discorsi di Mercato

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mag 2026, 16:57 UTC

Acquisizioni, Fusioni, Takeovers

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mag 2026, 16:57 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

18 mag 2026, 16:57 UTC

Discorsi di Mercato

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mag 2026, 16:54 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Doesn't Set Out Financial Details of Deal

18 mag 2026, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mag 2026, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mag 2026, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mag 2026, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Buys Canada's Modern Group of Companies

Confronto tra pari

Modifica del prezzo

Arcutis Biotherapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

62.43% in crescita

Previsioni per 12 mesi

Media 34.63 USD 62.43%

Alto 36 USD

Basso 33 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

12.42 / 14.93Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

157 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.